New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:17 EDTINCYIncyte to present data from multiple cancer programs at ASCO meeting
Incyte will present new data from its lead cancer programs focused on onco-inflammation, immuno-oncology and myeloproliferative neoplasms at the 50th Annual Meeting of the American Society of Clinical Oncology from May 30 to June 3. Data to be presented include full results from RECAP, the Phase II trial of ruxolitinib in combination with capecitabine in metastatic pancreatic cancer. Topline results showed an overall survival benefit in a pre-specified subgroup analysis of patients. Also being presented are preliminary findings from a Phase I/II study of Incyte’s IDO1 inhibitor, INCB24360, in combination with ipilimumab in patients with metastatic melanoma, designed to examine potential synergy with other cancer immunotherapies. Full results will be presented from the pivotal Phase III RESPONSE trial of ruxolitinib in patients with uncontrolled polycythemia vera, the first Phase III study to evaluate a JAK inhibitor as a treatment for patients with PV, which met its primary endpoint.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
08:25 EDTINCYIncyte management to meet with UBS
Subscribe for More Information
November 17, 2014
11:06 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
November 13, 2014
13:32 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
November 12, 2014
11:17 EDTINCYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 11, 2014
16:14 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
15:43 EDTINCYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use